Cannabis Science Presents Its African Drug Development Initiative at Major U.S.-Africa Policy Conference
IRVINE, CA–(Marketwired – Sep 27, 2017) – Cannabis Science, Inc. (
“CFA’s Ronald H. Brown African Affairs Series is an important annual event for Cannabis Science. In addition to this series, the Company presented at the Global Health Catalyst Summit at Harvard Medical School in April of this year, and we plan to present at the African Organization for Research and Training in Cancer (AORTIC) Conference in Rwanda in November,” stated Dr. Herman. “These important events allow the Company to share ideas and build on our current collaborations for research and multi-center clinical trials.”
During the Healthcare roundtable on Strengthening Healthcare Infrastructure in Africa, Cannabis Science’s President and CEO, Mr. Raymond Dabney, and the Company’s Chief Medical Officer (CMO), Dr. Allen Herman, presented an update on Cannabis Science’s African Drug Development Initiative which includes educational and job creation programs.
The theme of the Healthcare Roundtable was Reversing Africa’s Brain Drain: The Role of the African Diaspora in Strengthening the Healthcare Infrastructure of Africa, and the session explored strategies to invest in and develop Africa’s health workers, healthcare and social services infrastructure, logistics, surveillance and health information systems, healthcare governance, and drug supply systems. The roundtable was moderated by the Honorable Donna Christensen, former Member of the U.S. House of Representatives, and former Chair of the Congressional Black Caucus Health Braintrust; and Ambassador Bonnie Jenkins, Joint Visiting Fellow at the University of Pennsylvania Perry World House and Brookings Institution. Distinguished speakers included the Honorable Dr. Arikana Chihombori, the African Union’s Ambassador to the U.S.; Dr. John Nkengasong, Director of the Africa Centers for Disease Control and Prevention; Professor Akin Abayomi, Principal Investigator for the Global Emerging Pathogens Treatment Consortium (GET Africa); and Dr. Wilfred Ngwa, Global Health Catalyst Director at the Dana-Farber/Harvard Cancer Center.
“This is the third year that Cannabis Science has presented at CFA’s Ronald H. Brown African Affairs Series. Each year, we have been able to create new opportunities for our Company through active engagement with thought-leaders in our industry, as well as through the formation of new collaborations with individuals and institutions,” stated Mr. Dabney. “As a result of this year’s conference, we expect to accelerate our activities in a number of African countries.”
In addition to attending the AORTIC Conference in Rwanda, the Company will sponsor a special session on the Use of Cannabinoids to Treat Cancers. This session will focus on the potential use of cannabinoids in treating cancers and other indications, helping to close the global pain divide, and on establishing partnerships with key stakeholders worldwide to accelerate research, and possible clinical translation of cannabinoid-based medicines. Information on the AORTIC Conference can be viewed at http://aorticconference.org/.
Through Cannabis Science’s collaborations, the company is executing its research and development plan and initial results were recently published in the cancer research journal Frontiers in Oncology. The article can be viewed at http://journal.frontiersin.org/article/10.3389/fonc.2017.00208/full.
This publication titled, “Nanoparticle drones to target lung cancer with radiosensitizers and cannabinoids,” addresses drug delivery, and highlights an innovative strategy to deliver cannabinoids directly to cancer cells with minimal toxicities or side effects that have so far hampered clinical translation efforts.
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a ‘safe harbor’ for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company is detailed from time to time in the company’s reports filed with the Securities and Exchange Commission.
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=3171413